Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia

Sima Jeha*, Frederick Behm, Deqing Pei, John T. Sandlund, Raul C. Ribeiro, Bassem I. Razzouk, Jeffrey E. Rubnitz, Nobuko Hijiya, Scott C. Howard, Cheng Cheng, Ching Hon Pui

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

67 Scopus citations


CD20 expression is associated with inferior survival in adults with acute lymphoblastic leukemia (ALL). We analyzed the prognostic impact of CD20 expression in 353 children with B-cell precursor ALL treated in 3 consecutive St Jude Total Therapy studies. CD20 expression (> 20%) was found in 169 patients (48%) and was more frequent in patients between 1 and 10 years of age than in those younger than 1 or older than 10 years (P = .001). None of 14 patients with MLL-AF4 expressed CD20. There was no association between CD20 expression and E2A-PBX, TEL-AML1, ploidy, white blood cell count at diagnosis, or sex. In contrast to the experience in adult ALL, our patients with CD20 expression tended to have a better treatment outcome than those without the expression: 5-year event-free survival 84% ± 2.9% versus 78% ± 3.1% (P = .08). These data suggest that CD20 expression is not associated with inferior outcome in pediatric patients treated with contemporary regimens.

Original languageEnglish (US)
Pages (from-to)3302-3304
Number of pages3
Issue number10
StatePublished - Nov 15 2006

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this